Synthetic anticancer vaccine candidates: Rational design of antigenic peptide mimetics that activate tumor-specific T-cells

Journal of Medicinal Chemistry

Volumn 50, Issue 7, 2007, Pages 1598-1609

  Douat Casassus, Céline ^a,b   Marchand Geneste, Nathalie ^b   Diez, Elisabeth ^c   Gervois, Nadine ^c,d   Jotereau, Francine ^c,d   Quideau, Stéphane ^a,b  

^a INSTITUT EUROPÉEN DE CHIMIE ET BIOLOGIE   (France)

^b INSTITUT DES SCIENCES MOLÉCULAIRES   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GLUTAMYLLEUCYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE DERIVATIVE; HLA A2 ANTIGEN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; PEPTIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE CLONE; T LYMPHOCYTE;

EID: 34147119079     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0613368     Document Type: Article

References (75)

1. Kagi, D.; Hengartner, H. Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Curr. Opin. Immunol. 1996, 8, 472-477.
2. Greenberg, P. D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 1991, 49, 281-355.
3. Cresswell, P. Antigen processing and presentation. Immunol. Rev. 2005, 205, 5-7.
4. Davis, M. M.; Boniface, J. J.; Reich, Z.; Lyons, D. S.; Hampl, J.; Arden, B.; Chien, Y. Ligand recognition by alpha beta T cell receptors. Annu. Rev. Immunol. 1998, 16, 523-544.
5. (a) Larche, M.; Wraith, D. C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 2005, 11, 69-76.
6. (b) Boon, T.; Coulie, P. G.; Van den Eynde, B. J.; van der Bruggen, P. Human T cell responses against melanoma. Annu. Rev. Immunol. 2006, 24, 175-208.
7. Rosenberg, S. A.; Yang, J. C.; Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10, 909-915.
8. Starr, T. K.; Jameson, S. C.; Hogquist, K. A. Positive and negative T cell selection. Annu. Rev. Immunol. 2003, 21, 139-176.
9. (a) Kawakami, Y.; Eliyahu, S.; Sakaguchi, K.; Robbins, P. F.; Rivoltini, L.; Yannelli, J. R.; Appella, E.; Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 1994, 180, 347-352.
10. (b) Coulie, P. G.; Brichard, V.; Van Pel, A.; Wölfel, T.; Schneider, J.; Traversari, C.; Mattel, E.; De Plaen, C.; Lurquin, J.; Szikora, P.; Renauld, J. C.; Boon, T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1994, 180, 35-42.
11. Valmori, D.; Fonteneau, J. F.; Maranon Lizana, C.; Gervois, N.; Liénard, D.; Rimoldi, D.; Jongeneel, C. V.; Jotereau, F.; Cerottini, J. C.; Romero, P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogs. J. Immunol 1998, 160, 1750-1758.
12. Blanchet, J. S.; Valmori, D.; Dufau, I.; Ayyoub, M.; Nguyen, C.; Guillaume, P.; Monsarrat, B.; Cerottini, J. C.; Romero, P.; Gairin, J. E. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy. J. Immunol. 2001, 167, 5852-5861.
13. Brinckerhoff, L. H.; Kalashnikov, V. V.; Thompson, L. W.; Yamshchikov, G. V.; Pierce, R. A.; Galavotti, H. S.; Engelhard, V. H.; Slingluff, C. L. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-27-35 peptide: Implications for peptide vaccines. Int. J. Cancer 1999, 83, 326-334.
14. (a) Hin, S.; Bianco, A.; Zabel, C.; Jung, G.; Walden, P. Mimetics of a T cell epitope based on poly-N-acylated amine backbone structures induce T cells in vitro and in vivo. J. Biol. Chem. 2001, 276, 48790-48796.
15. (b) Bianco, A.; Brock, C.; Zabel, C.; Walk, T.; Walden, P.; Jung, G. New synthetic non-peptide ligands for classical major histocompatibility complex class 1 molecules. J. Biol. Chem. 1998, 273, 28759-28765.
16. Hofbauer, G. F.; Kamarashev, J.; Geertsen, R.; Boni, R.; Dummer, R. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res. 1998, 8, 337-343.
17. Kawakami, Y.; Eliyahu, S.; Delgado, C. H.; Robbins, P. F.; Sakaguchi, K.; Appella, E.; Yannelli, J. R.; Adema, G. J.; Miki, T.; Rosenberg, S. A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. 1994, 91, 6458-6462.
18. Pittet, M. J.; Valmori, D.; Dunbar, P. R.; Speiser, D. E.; Lienard, D.; Lejeune, F.; Fleischhauer, K.; Cerundolo, V.; Cerottini, J. C.; Romero, P. High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med 1999, 190, 705-716.
19. Romero, P.; Gervois, N.; Schneider, J.; Escobar, P.; Valmori, D.; Pannetier, C.; Steinle, A.; Wolfel, T.; Lienard, D.; Brichard, V.; van Pel, A.; Jotereau, F.; Cerottini, J. C. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted MelanA/MART-1 antigenic peptide in melanoma. J. Immunol 1997, 159, 2366-2374.
20. Ruppert, J.; Sidney, J.; Celis, E.; Kubo, R. T.; Grey, H. M.; Sette, A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell, 1993, 74, 929-937.
21. SHz, P.; Michielin, O.; Cerottini, J. C.; Luescher, I.; Romero, P.; Karplus, M.; Wiley, D. C. Structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoina tumor-antigen peptide complexes. J. Immunol. 2001, 167, 3276-3284.
22. (a) Ayyoub, M.; Zippelius, A.; Pittet, M. J.; Rimoldi, D.; Valmori, D.; Cerottini, J. C.; Romero, P.; Lejeune, F.; Lienard, D.; Speiser, D. E. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin. Cancer Res. 2003, 9, 669-677.
23. (b) Lienard, D.; Rimoldi, D.; Marchand, M.; Dietrich, P. Y.; van Baren, N.; Geldhof, C.; Batard, P.; Guillaume, P.; Ayyoub, M.; Pittet, M. J.; Zippelius, A.; Fleischhauer, K.; Lejeune, F.; Cerottini, J. C.; Romero, P.; Speiser, D. E. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun. 2004, 4, 1-19.
24. (a) Rudolph, M. G.; Wilson, I. A. The specificity of TCR/pMHC interaction. Curr. Opin. Immunol. 2002, 14, 52-65.
25. (b) Rudolph, M. G.; Stanfield, R. L.; Wilson, I. A. Annu. Rev. Immunol. 2006, 24, 419-466.
26. Garboczi, D. N.; Ghosh, P.; Utz, U.; Fan, Q. R.; Biddison, W. E.; Wiley, D. C. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996, 384, 134-140.
27. (a) Pinilla, C.; Martin, R.; Gran, B.; Appel, J. R.; Boggiano, C.; Wilson, D. B.; Houghten, R. A. Exploring immunological specificity using synthetic peptide combinatorial libraries. Curr. Opin. Immunol. 1999, 11, 193-202.
28. (b) Rubio-Godoy, V.; Dutoit, V.; Zhao, Y.; Simon, R.; Guillaume, P.; Houghten, R.; Romero, P.; Cerottini, J. C.; Pinilla, C.; Valmori, D. Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL. J. Immunol. 2002, 169, 5696-5707.
29. (c) Pinilla, C.; Rubio-Godoy, V.; Dutoit, V.; Guillaume, P.; Simon, R.; Zhao, Y.; Houghten, R. A.; Cerottini, J. C.; Romero, P.; Valmori, D. Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes. Cancer Res. 2001, 61, 5153-5160.
30. (d) Douat-Casassus, C.; Marchand Geneste, N.; Diez, E.; Aznar, C.; Picard, P.; Geoffre, S.; Huet, A.; Bourguet-Kondracki, M.-L.; Gervois, N.; Jotereau, F.; Quideau, S. Covalent modification of a melanoma-derived antigenic peptide with a natural quinone methide. Preliminary chemical, molecular modelling and immunological evaluation studies. Mol BioSyst. 2006, 2, 240-249.
31. (e) Gagnon, S. J.; Borbulevych, O. Y.; Davis-Harrison, R. L.; Turner, R. V.; Damirjian, M.; Wojnarowicz, A.; Biddison, W. E.; Baker, B. M. T cell receptor recognition via cooperative conformational plasticity. J. Mol. Biol 2006, 363, 228-243.
32. Venkatachalam, C. M.; Jiang, X.; Oldfield, T.; Waldman, M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J. Mol. Graph. Model. 2003, 21, 289-307.
33. (a) Apostolopoulos, V.; Yu, M.; Corper, A. L.; Li, W.; McKenzie, I. F.; Teyton, L.; Wilson, I. A.; Plebanski, M. Crystal structure of a non-canonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors. J. Mol. Biol. 2002, 318, 1307-1316.
34. (b) Apostolopoulos, V.; Yu, M.; Corper, A. L.; Teyton, L.; Pietersz, G. A.; McKenzie, I. F.; Wilson, I. A.; Plebanski, M. Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: A new approach for vaccine design. J. Mol. Biol. 2002, 318, 1293-1305.
35. (c) Saper, M. A.; Bjorkman, P. J.; Wiley, D. C. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. J. Mol. Biol. 1991, 219, 277-319.
36. (d) Hillig, R. C.; Coulie, P. G.; Stroobant, V.; Saenger, W.; Ziegler, A.; Hulsmeyer, M. High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene. J. Mol. Biol. 2001, 310, 1167-1176.
37. Quesnel, A.; Zerbib, A.; Connan, F.; Guillet, J. G.; Briand, J. P.; Choppin, J. Synthesis and antigenic properties of reduced peptide bond analogues of an immunodominant epitope of the melanoma MART-1 protein. J. Pept. Sci. 2001, 7, 157-165.
38. (a) Calbo, S.; Guichard, G.; Bousso, P.; Muller, S.; Kourilsky, P.; Briand, J. P.; Abastado, J. P. Role of peptide backbone in T cell recognition. J. Immunol. 1999, 162, 4657-4662.
39. (b) Stemmer, C.; Quesnel, A.; Prévost-Blondel, A.; Zimmermann, C.; Muller, S.; Briand, J. P.; Pircher, H. Protection against lymphocytic choriomeningitis virus infection induced by a reduced peptide bond analogue of the H-2Db-restricted CD8+ T cell epitope GP33. J. Biol. Chem. 1999, 274, 5550-5556.
40. (c) Ayyoub, M.; Mazarguil, H.; Monsarrat, B.; Van den Eynde, B.; Gairin, J. E. A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells. J. Biol. Chem. 1999, 274, 10227-10234.
41. (a) Krebs, S.; Lamas, J. R.; Rognan, D. Substituting nonpeptidic spacers for the T cell receptor-binding part of class 1 major histocompatibility complex-binding peptides. J. Biol. Chem. 1998, 273, 19072-19079.
42. (b) Rognan, D.; Scapozza, L.; Folkers, G.; Daser, A. Rational design of nonnatural peptides as high-affinty ligands for the HLA-B*2705 human leukocyte antigen. Proc. Natl. Acad. Sci. 1995, 92, 753-747.
43. (a) Nielsen, P. E. Peptide Nucleic Acids: Protocols and Applications; Horizon Scientific Press: Portland, U.K., 1999.
44. (b) Baker, E. S.; Hong, J. W.; Gaylord, B. S.; Bazan, G. C.; Bowers, M. T. PNA/dsDNA complexes: site specific binding and dsDNA biosensor applications. J. Am. Chem. Soc. 2006, 128, 8484-8492.
45. Guichard, G.; Zerbib, A.; Le Gal, F.-A.; Hoebeke, J.; Connan, F.; Choppin, J.; Briand, J.-P.; Guillet, J.-G. Melanoma Peptide MART-1(27-35.) Analogues with Enhanced Binding Capacity to the Human Class I Histocompatibility Molecule HLA-A2 by Introduction of β-Amino Acid Residue: Implications for Recognition by Tumor-Infiltrating Lymphocytes. J. Med. Chem. 2000, 43, 3803-3808.
46. (a) Weerapana, E.; Imperiali, B. Peptides to peptidomimetics: towards the design and synthesis of bioavailable inhibitors of oligosaccharyl transferase. Org. Biomol. Chem 2003, 1, 93-99.
47. (b) Qian, Y.; Blaskovich, M.; Saleem, M.; Seong, M.; Wathen, S. P.; Hamilton, A. D.; Sebti, S. M. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase. J. Biol. Chem. 1994, 269, 12410-12413.
48. (c) Cristau, M.; Devin, C.; Oiry, C.; Chaloin, O.; Amblard, M.; Bernad, N.; Heitz, A.; Fehrentz, J.-A.; Martinez, J. Synthesis and biological evaluation of bombesin constrained analogues. J. Med. Chem. 2000, 43, 2356-2361.
49. (d) Lunney, E. A.; Para, K. S.; Rubin, J. R.; Humblet, C.; Fergus, J. H.; Marks, J. S.; Sawyer, T. K. Structure-based design of a novel Series of nonpeptide ligands that bind to the pp60src SH2 domain. J. Am. Chem. Soc. 1997, 119, 12471-12476.
50. Bolin, D. R.; Swain, A. L.; Sarabu, R.; Berthel, S. J.; Gillespie, P.; Huby, N. J.; Makofske, R.; Orzechowski, L.; Perrotta, A.; Toth, K.; Cooper, J. P.; Jiang, N.; Falcioni, F.; Campbell, R.; Cox, D.; Gaizband, D.; Belunis, C. J.; Vidovic, D.; Ito, K.; Crowther, R.; Kammlott, U.; Zhang, X.; Palermo, R.; Weber, D.; Guenot, J.; Nagy, Z.; Olson, G. L. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. J. Med. Chem. 2000, 43, 2135-2148.
51. Nagy, A.; Armatis, P.; Cai, R. Z.; Szepeshazi, K.; Halmos, G.; Schally, A. V. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc. Natl. Acad. Sci. 1997, 94, 652-656.
52. Douat, C.; Heitz, A.; Martinez, J.; Fehrentz, J. A. Synthesis of N-protected-amino aldehydes from their morpholine amide derivatives. Tetrahedron Lett. 2000, 41, 37-40.
53. Shannon, S. K.; Peacock, M. J.; Kates, S. A.; Barany, G. Solid-phase synthesis of lidocaine and procainamide analogues using backbone amide linker (BAL) anchoring. J. Comb. Chem. 2003, 5, 860-868.
54. Burkoth, T. S.; Fafarman, A. T.; Charych, D. H.; Connolly, M. D.; Zuckermann, R. N. Incorporation of unprotected heterocyclic side chains into peptoid oligomers via solid-phase submonomer synthesis. J. Am. Chem. Soc. 2003, 125, 8841-8845.
55. Olivos, H. J.; Alluri, P. G.; Reddy, M. M.; Salony, D.; Kodadek, T. Microwave-assisted solid-phase synthesis of peptoids. Org. Lett. 2002, 4, 4057-4059.
56. Uno, T.; Beausoleil, E.; Goldsmith, R. A.; Levine, B. H.; Zuckermann, R. N. New submonomers for poly N-substituted glycines (peptoids). Tetrahedron Lett. 1999, 40, 1475-1478.
57. Kruijtzer, J. A. W.; Hofmeyer, L. J. F.; Heerma, W.; Versluis, C.; Liskamp, R. M. J. Solid-phase syntheses of peptoids using Fmoc-protected N-substituted glycines: The synthesis of (retro)peptoids of Leu-enkephalin and substance P. Chem. Eur. J. 1998, 4, 1570-1580.
58. Fonteneau, J. F.; Le Drean, E.; Le Guiner, S.; Gervois, N.; Diez, E.; Jotereau, F. Heterogeneity of biologic responses of melanoma-specific CTL. J. Immunol. 1997, 159, 2831-2839.
59. Wu, L. C.; Tuot, D. S.; Lyons, D. S.; Garcia, K. C.; Davis, M. M. Two-step binding mechanism for T-cell receptor recognition of peptide-MHC. Nature 2002, 418, 552-558.
60. Krogsgaard, M.; Davis, M. M. How T cells "see" antigen. Nature Immunol. 2005, 6, 239-245.
61. Reiser, J. B.; Darnault, C.; Gregoire, C.; Mosser, T.; Mazza, G.; Kearney, A.; Van der Merwe, P. A.; Fontecilla-Camps, J. C.; Housset, D.; Malissen, B. CDR3 loop flexibility contributes to the degeneracy of TCR recognition. Nature Immunol. 2003, 4, 241-247.
62. Valmori, D.; Gervois, N.; Rimoldi, D.; Fonteneau, J. F.; Bonelo, A.; Lienard, D.; Rivoltini, L.; Jotereau, F.; Cerottini, J. C.; Romero, P. Diversity of the fine specificity displayed by HLA-A0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide. J. Immunol. 1998, 161, 6956-6962.
63. Gasteiger, J.; Marsili, M. A new model for calculating atomic charges in molecules. Tetrahedron Lett. 1978, 19, 3181-3184.
64. Vieth, M.; Hirst, J. D.; Dominy, B. N.; Daigler, H.; Brooks, C. L. Assessing search strategies for flexible docking. J. Comput. Chem. 1998, 19, 1623-1631.
65. (a) Krapcho, A. P.; Kuell, C. S. Mono-protected diamines N-tert-Butoxycarbonyl-α,ω-alkanediamines from α,ω- alkanediamines. Synth. Commun. 1990, 20, 2559-2564.
66. (b) Kurtan, T.; Nesnas, N.; Li, Y.-Q.; Huang, X.; Nakanishi, K.; Berova, N. chiral recognition by CD-sensitive dimeric zinc porphyrin host. 1. chiroptical protocol for absolute configurational assignments of monoalcohols and primary monoamines. J. Am. Chem. Sac. 2001, 123, 5962-5973.
67. (a) Aldrian-Herrada, G.; Rabie, A.; Wintersteiger, R.; Brugidou, J. Solid-phase synthesis of peptide nucleic acid (PNA) monomers and their oligomerization using disulphide anchoring linkers. J. Pept. Sci. 1998, 4, 266-281.
68. Jackson, R. W.; Tabone, J. C.; Howbert, J. J. Identification of TNF-α inhibitors from a split-Pool library based on a tyrosine-proline peptidomimetic scaffold. Biol. Med. Chem. Lett. 2003, 13, 205-208.
69. (a) Lloyd-Williams, P.; Albericio, F.; Giralt, E. Chemical Approaches to the Synthesis of Peptide s and Proteins; CRC Press: Boca Raton, FL, 1997.
70. (b) Chan, C.; White, P. D. Fmoc Solid Phase Peptide Synthesis: a practical approach; Oxford Press: New York, 2000.
71. Uno, T.; Beausoleil, E.; Goldsmith, R. A.; Levine, B. H.; Zuckermann, R. N. New submonomers for poly N-substituted glycines (peptoids). Tetrahedron Lett. 1999, 40, 1475-1478.
72. (a) Gervois, N.; Guilloux, Y.; Diez, E.; Jotereau, F. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J. Exp. Med. 1996, 183, 2403-2407.
73. (b) Vignard, V.; Lemercier, B.; Lim, A.; Pandolfino, M. C.; Guilloux, Y.; Khammari, A.; Rabu, C.; Echasserieau, K.; Lang, F.; Gougeon, M. L.; Dreno, B.; Jotereau, F.; Labarriere, N. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J. Immunol 2005, 175, 4797-4805.
74. Jotereau, F.; Pandolfino, M. C.; Boudart, D.; Diez, E.; Dreno, B.; Douillard, J. Y.; Muller, J. Y.; LeMevel, B. High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J. Immunother. 1991, 10, 405-411.
75. Jung, T.; Schauer, U.; Heusser, C.; Neumann, C.; Rieger, C. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods 1993, 159, 197-207.